ALNY - Regeneron says Q3 results to be impacted by $100M IPR&D expense
2023-10-05 16:53:53 ET
More on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
- Regeneron and Intellia expand gene editing partnership
- Regeneron nabs FDA priority review for lymphoma therapy
For further details see:
Regeneron says Q3 results to be impacted by $100M IPR&D expense